Covance Company Profile (NYSE:CVD)

About Covance

Covance logoCovance Inc. is engaged in drug development services. The Company provides a range of early-stage and late-stage product development services to the pharmaceutical and biotechnology industries. The Company also provides laboratory testing services to the chemical, agrochemical and food industries. The Company operates in two segments: early development services, and late-stage development services. The early development services include lead optimization services, preclinical services and clinical pharmacology services. The late-stage development services include central laboratory, Phase II-IV clinical development, and market access services.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Life Sciences Tools & Services
  • Sub-Industry: Life Sciences Tools & Services
  • Exchange: NYSE
  • Symbol: CVD
  • CUSIP: 22281610
Key Metrics:
  • Previous Close: $106.00
  • 50 Day Moving Average: $97
  • 200 Day Moving Average: $82
  • 52-Week Range: $58.00 - $107.00
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: 21.20
  • P/E Growth: 0
  • Market Cap: $N/A
Additional Links:
Companies Related to Covance:

Analyst Ratings

Consensus Ratings for Covance (NYSE:CVD) (?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for Covance (NYSE:CVD)
DateFirmActionRatingPrice TargetDetails
11/7/2014Jefferies GroupDowngradeBuy -> Hold$98.00 -> $104.00View Rating Details
11/5/2014KeyCorpDowngradeBuy -> Hold$100.00View Rating Details
11/4/2014William BlairDowngradeOutperform -> Market PerformView Rating Details
11/4/2014JPMorgan Chase & Co.DowngradeOverweight -> NeutralView Rating Details
11/4/2014Credit Suisse Group AGDowngradeOutperform -> Neutral$97.00 -> $103.00View Rating Details
11/4/2014Robert W. BairdDowngradeOutperform -> Neutral$99.00 -> $105.00View Rating Details
11/4/2014Raymond James Financial Inc.DowngradeOutperform -> Market PerformView Rating Details
11/3/2014Piper Jaffray Cos.DowngradeOverweight -> Neutral$99.00 -> $103.00View Rating Details
(Data available from 10/24/2014 forward)


Earnings History for Covance (NYSE:CVD)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/4/2015Q414$0.96$0.97$631.30 million$634.00 millionViewN/AView Earnings Details
11/3/2014Q314$0.98$0.98$651.00 million$627.00 millionViewN/AView Earnings Details
7/29/2014Q214$0.93$0.95$639.80 million$687.10 millionViewN/AView Earnings Details
5/1/2014Q114$0.90$0.90$632.01 million$620.10 millionViewN/AView Earnings Details
2/4/2014Q413$0.84$0.87$613.80 million$623.00 millionViewN/AView Earnings Details
10/29/2013Q313$0.80$0.83$594.30 million$606.70 millionViewN/AView Earnings Details
7/30/2013Q2 2013$0.77$0.78$586.12 million$644.00 millionViewN/AView Earnings Details
5/1/2013Q1 2013$0.72$0.75$569.34 million$580.20 millionViewN/AView Earnings Details
1/24/2013Q4 2012$0.71$0.73$548.84 million$562.20 millionViewN/AView Earnings Details
11/5/2012Q312$0.67$0.72$546.52 million$597.66 millionViewN/AView Earnings Details
7/25/2012$0.64$0.65ViewN/AView Earnings Details
5/2/2012$0.60$0.68ViewN/AView Earnings Details
1/25/2012$0.73$0.73ViewN/AView Earnings Details
11/2/2011$0.70$0.71ViewN/AView Earnings Details
7/27/2011$0.65$0.66ViewN/AView Earnings Details
5/5/2011$0.58$0.60ViewN/AView Earnings Details
1/26/2011$0.53$0.56ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Covance (NYSE:CVD)
Current Year EPS Consensus Estimate: $4 EPS
Next Year EPS Consensus Estimate: $5 EPS


Dividend History for Covance (NYSE:CVD)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Covance (NYSE:CVD)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/22/2014Brian H NuttInsiderSell1,127$103.51$116,655.77View SEC Filing  
12/18/2014Joseph L HerringCEOSell32,692$103.02$3,367,929.84View SEC Filing  
12/10/2014John E WatsonVPSell15,200$102.94$1,564,688.00View SEC Filing  
9/9/2014Joseph L HerringCEOSell32,200$85.13$2,741,186.00View SEC Filing  
2/20/2014James LovettVPSell14,955$102.47$1,532,438.85View SEC Filing  
2/10/2014Brian NuttInsiderSell1,808$100.12$181,016.96View SEC Filing  
2/10/2014Richard CiminoEVPSell13,000$99.10$1,288,300.00View SEC Filing  
2/10/2014Sandra HeltonDirectorSell2,800$99.03$277,284.00View SEC Filing  
9/20/2013Richard CiminoEVPSell16,000$84.86$1,357,760.00View SEC Filing  
9/5/2013Sandra L HeltonDirectorSell3,000$81.92$245,760.00View SEC Filing  
9/5/2013William E KlitgaardVPSell25,323$81.44$2,062,305.12View SEC Filing  
8/21/2013Deborah KellerEVPSell15,900$83.12$1,321,608.00View SEC Filing  
8/16/2013Robert BarchiDirectorSell13,667$82.78$1,131,354.26View SEC Filing  
8/2/2013Gary CostleyDirectorSell7,467$82.77$618,043.59View SEC Filing  
8/2/2013Joseph HerringCEOSell100,000$82.54$8,254,000.00View SEC Filing  
6/27/2013Joseph L HerringCEOSell13,259$77.00$1,020,943.00View SEC Filing  
6/19/2013Joseph L HerringCEOSell22,391$78.03$1,747,169.73View SEC Filing  
5/15/2013James W LovettVPSell10,259$77.00$789,943.00View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for Covance (NYSE:CVD)
DateHeadline logoCovance Receives Frost & Sullivan Asia Pacific CRO Growth Excellence Leadership Award Three Years Running (NYSE:CVD) - October 12 at 9:49 PM logoLabCorp (LH) Tops Q2 Earnings, View Up, to Buy Sequenom (NYSE:CVD) - July 27 at 1:16 PM logoLabCorp Sees Balanced Growth; Covance Synergy on Track (NYSE:CVD) - June 21 at 7:00 AM logoLaboratory Corp. of America Looks Pretty Healthy (NYSE:CVD) - June 2 at 11:00 AM logoLabCorp (LH) Posts Strong Q1; Covance Synergy Continues (NYSE:CVD) - May 17 at 8:07 AM logoEarly Development, Central Labs Businesses: Strong Demand in 1Q16 (NYSE:CVD) - May 8 at 7:05 AM logoINC Research Holdings In The Spotlight As Rumors Of A Suitor Circulate (NYSE:CVD) - May 3 at 7:14 AM logoAbbott Laboratories Acquisition (NYSE:CVD) - April 29 at 7:57 AM logoLabCorp (LH) Tops Q1 Earnings and Sales, Raises Guidance (NYSE:CVD) - April 25 at 10:02 AM logoTesting LabCorp's Deal Plans (NYSE:CVD) - April 19 at 11:00 AM logoLabCorp Hires Jonathan Zung as Group President of Clinical Development and Commercialization Services for Covance Drug Development (NYSE:CVD) - April 11 at 10:41 AM logoLabCorp (LH): Revenues Strong on Balanced Organic Growth (NYSE:CVD) - February 23 at 4:13 PM logoLabCorp's King: 2015 was 'transformative' (NYSE:CVD) - February 18 at 1:00 PM logoLabCorp Q4 Earnings Miss, Revenues Top; Currency Bothers (NYSE:CVD) - February 18 at 11:02 AM logoLabCorp Tops Revenues, Misses on Earnings in Q4 (NYSE:CVD) - February 18 at 7:45 AM logoWill LabCorp (LH) Disappoint Earnings Estimates in Q4? (NYSE:CVD) - February 15 at 1:00 PM logoLabCorp Poised on Strategic Initiatives, Currency Woes Linger (NYSE:CVD) - January 5 at 2:35 PM logoLabCorp (LH) Posts Mixed Q3, Covance Synergy on Track (NYSE:CVD) - December 1 at 2:15 PM logoNeoGenomics Amends Strategic Alliance Agreement with Covance Central Laboratory Services (NYSE:CVD) - October 28 at 8:17 PM logoLaboratory Corp. of America (LH) Stock Gains on Earnings Beat (NYSE:CVD) - October 26 at 3:57 PM logoCovance deal continues to fuel revenue, earnings growth for LabCorp (NYSE:CVD) - October 26 at 2:00 PM logoLabCorp Q3 Earnings in Line, Revenues Strong; View Revised (NYSE:CVD) - October 26 at 9:50 AM logoLabCorp (LH) Q3 Earnings in Line, Revenues Beat Estimates (NYSE:CVD) - October 26 at 8:10 AM logo[$$] LabCorp's Sales Soars Following Covance Buy (NYSE:CVD) - October 26 at 7:51 AM logoLabCorp expands beyond labwork with purchase of food and beverage company (NYSE:CVD) - October 23 at 2:20 PM logoCovance to Open Second Current Good Manufacturing Practice (cGMP) Pharmacy in U.S. (NYSE:CVD) - September 21 at 4:35 PM logoLaboratory Corp Of America (LH) Earnings Report: Q2 2015 Conference Call Transcript (NYSE:CVD) - July 28 at 5:39 PM logoLabCorp Announces New Covance Leadership (NYSE:CVD) - July 28 at 7:56 AM logoWill LabCorp (LH) Keep its Earnings Streak Alive in Q2? - Analyst Blog (NYSE:CVD) - July 24 at 2:25 PM logoCovance Opens Fit-for-Purpose Dallas Clinical Research Unit (NYSE:CVD) - July 23 at 8:50 AM logoKeyBanc Starts Lab Corp Of America At Overweight, But Indebtedness Is A Concern (NYSE:CVD) - June 16 at 10:45 AM logoLabCorp is Scheduled to Present at the Goldman Sachs 36th Annual Global Healthcare Conference (NYSE:CVD) - June 2 at 9:29 AM


Covance (NYSE:CVD) Chart for Monday, October, 24, 2016

Last Updated on 10/24/2016 by Staff